Celldex Therapeutics Inc. said its therapeutic vaccine to treat the most common and most aggressive form of brain tumor has been successful in temporarily halting the progression of the disease for about two-thirds of the patients in a Phase 2 study.
The Needham-based company said that its single-arm Phase 2 study for the therapeutic cancer vaccine, called rindopepimut, showed that 66 percent of patients were disease progression-free at eight and a half months from diagnosis or five and a half months from start of vaccination. The company said this is a statistically significant increase over the expected progression-free time period without the vaccine candidate.
